ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 27 October to 2 November 2025

The 6 most important of the 6 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Gastroenterology · Lancet Gastroenterol Hepatol · 2025-10-28

In 238 patients with primary biliary cholangitis and moderate-to-severe itch, linerixibat improved itch over 24 weeks vs placebo (WI-NRS change −2·86 vs −2·15; difference −0·72, p=0·0013), but diarrhoea (61% vs 18%) and serious adverse events (12% vs 3%) were more common.

RCTn = 238
Hirschfield et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Cardiology · Europace · 2025-10-31

Secondary analysis of TAILORED-AF in women with persistent AF (21% of 370): AI-guided tailored ablation vs PVI alone gave higher single-procedure freedom from AF (76% vs 50%) and any atrial arrhythmia (56% vs 38%) at 12 months.

Secondary analysisn = 370
Deisenhofer et al. Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.